Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Tomiyama, S. Kosugi (2005)
Autoantigenic Epitopes on Platelet GlycoproteinsInternational Journal of Hematology, 81
G. Pineo (2007)
Chronic Idiopathic Thrombocytopenic Purpura
(2012)
Recog - nition of highly restricted regions in the β - propeller domain of αIIb by platelet - associated anti - αIIbβ 3 autoantibodies in primary immune thrombocytopenia
C. Choi, B. Kim, J. Seo, S. Shin, Yeul-Hong Kim, Jun Kim, S. Sohn, Jae Kim, D. Shin, H. Ryoo, K. Lee, Je Lee, I. Chung, Hyeoung-Joon Kim, J. Kwak, C. Yim, J. Ahn, Jung Lee, Y. Park (2001)
Response to high‐dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patientsAmerican Journal of Hematology, 66
J. Kelton, W. Murphy, Anne Lucarelli, Judy Garvey‐Williams, Aurelio Santos, Ralph Meyer, P. Powers (1989)
A prospective comparison of four techniques for measuring platelet‐associated IgGBritish Journal of Haematology, 71
Y. Kanda (2012)
Investigation of the freely available easy-to-use software ‘EZR' for medical statisticsBone Marrow Transplantation, 48
T. Brighton, S. Evans, P. Castaldi, C. Chesterman, B. Chong (1996)
Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias.Blood, 88 1
D. Provan, D. Arnold, J. Bussel, B. Chong, N. Cooper, T. Gernsheimer, W. Ghanima, B. Godeau, T. González‐López, J. Grainger, M. Hou, C. Kruse, V. Mcdonald, M. Michel, A. Newland, S. Pavord, F. Rodeghiero, M. Scully, Y. Tomiyama, R. Wong, F. Zaja, D. Kuter (2019)
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.Blood advances, 3 22
Y. Kurata, S. Hayashi, T. Kiyoi, S. Kosugi, H. Kashiwagi, S. Honda, Y. Tomiyama (2001)
Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia.American journal of clinical pathology, 115 5
Masataka Kuwana, Yoshiyuki Kurata, Kingo Fujimura, K. Fujisawa, Hideo Wada, Toshiro Nagasawa, S. Nomura, Tetsuhito Kojima, Hideo Yagi, Yasuo Ikeda (2006)
Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi‐center prospective studyJournal of Thrombosis and Haemostasis, 4
C. Neunert, N. Noroozi, G. Norman, G. Buchanan, Jennifer Goy, I. Nazi, J. Kelton, D. Arnold, D. Arnold (2015)
Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic reviewJournal of Thrombosis and Haemostasis, 13
H. Kashiwagi, Y. Tomiyama (2013)
Pathophysiology and management of primary immune thrombocytopeniaInternational Journal of Hematology, 98
R. Mcmillan, Lei Wang, P. Tani (2003)
Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP)Journal of Thrombosis and Haemostasis, 1
F. Palandri, N. Polverelli, L. Catani, D. Sollazzo, M. Romano, M. Levorato, N. Vianelli (2014)
The choice of second‐line therapy in steroid‐resistant immune thrombocytopenia: Role of platelet kinetics in a single‐centre long‐term studyAmerican Journal of Hematology, 89
J. Pizzuto, R. Ambriz (1984)
Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis.Blood, 64 6
Mikiko Sakuragi, S. Hayashi, Miho Maruyama, O. Kabutomori, T. Kiyokawa, K. Nagamine, H. Kato, H. Kashiwagi, Y. Kanakura, Y. Tomiyama (2015)
Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disordersInternational Journal of Hematology, 101
F. Rodeghiero, R. Stasi, T. Gernsheimer, M. Michel, D. Provan, D. Arnold, J. Bussel, D. Cines, B. Chong, N. Cooper, B. Godeau, K. Lechner, M. Mazzucconi, R. Mcmillan, M. Sanz, P. Imbach, V. Blanchette, T. Kühne, M. Ruggeri, J. George (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.Blood, 113 11
M. Tsuda, S. Imai, H. Suzuki, Y. Mori, A. Degutch, I. Ookubo, N. Katayama, H. Wada, N. Minami, K. Degutch (1988)
[Measurement of platelet antibody in various diseases].[Rinsho ketsueki] The Japanese journal of clinical hematology, 29 3
Objective: Platelet-associated immunoglobulin G (PA-IgG) refers to IgG attached to the surface of platelets, while the immature platelet fraction (IPF) reflects the state of platelet production in bone marrow. Since PA-IgG and IPF are increased in patients with immune thrombocytopenia (ITP), reflecting amounts of platelet antibodies and compensatory platelet production, respectively, we hypothesized that these laboratory findings may provide useful markers for predicting treatment response in patients with ITP. We therefore retrospectively investigated associations between levels of these markers at diagnosis and response to first-line therapy in patients with ITP. Methods: Forty-three patients diagnosed with ITP at Oita Kouseiren Tsurumi Hospital between May 2010 and November 2018 were included. Patients were divided into 2 groups based on response to corticosteroid as first-line therapy. Laboratory findings were compared between responders and nonresponders. Results: Median PA-IgG was 285 ng/10<sup>7</sup> cells (range, 45.5–18,200 ng/10<sup>7</sup> cells), and median IPF was 15.5% (range, 5.4–62.1%). Median levels were higher than the respective upper limits of normal range (PA-IgG, 0–46 ng/10<sup>7</sup> cells; IPF, 1.1–9.5%). First-line therapy was performed using standard-dose prednisolone (0.5–1.0 mg/kg/day) in 32 patients and high-dose dexamethasone (40 mg/day, 4 days) or methylprednisolone (125–1,000 mg/day, 3–4 days) in 11 patients. Twenty-four patients (55.8%) responded to first-line therapy. In univariate analysis, type of corticosteroid (p = 0.17) tended to differ between groups but did not differ significantly, and no difference in IPF level was apparent between responders (15.35%; range, 5.4–41.5%) and nonresponders (16.7%; range, 6.3–62.1%; p = 0.15). PA-IgG was significantly higher among nonresponders (430 ng/10<sup>7</sup> cells; range, 101–18,200 ng/10<sup>7</sup> cells) than among responders (254.5 ng/10<sup>7</sup> cells; range, 45.5–470 ng/10<sup>7</sup> cells; p = 0.004). Multivariate analysis revealed PA-IgG was independently associated with response to first-line therapy (odds ratio, 1.000; 95% confidence interval, 1.000–1.010; p = 0.029). Conclusion: Our data suggested that PA-IgG at diagnosis could offer a useful predictor of response to first-line corticosteroid therapy for ITP.
Acta Haematologica – Karger
Published: Sep 1, 2021
Keywords: Immune thrombocytopenia; Platelet-associated immunoglobulin G; Immature platelet fraction
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.